Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26580901 | 0.87 | KDM4E (0.35) | KDM4EMAPK1HSD17B10NPC1RAB9A | |
| SCHEMBL24785024 | 0.82 | ALDH1A1 (0.47) | HSD17B10NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL445465 | 0.80 | AKR1A1 (0.38) | KDM4EMAPK1HSD17B10 | |
| SCHEMBL26580893 | 0.78 | MAPK1 (0.39) | KDM4EMAPK1HSD17B10NPC1RAB9A | |
| SCHEMBL25905288 | 0.75 | MAPK1 (0.39) | KDM4EMAPK1HSD17B10NPC1RAB9A | |
| SCHEMBL12032789 | 0.73 | KDM4E (0.43) | KDM4EMAPK1HSD17B10NPC1RAB9A | |
| SCHEMBL17339833 | 0.71 | HSD17B10 (0.38) | KDM4EMAPK1HSD17B10NPC1RAB9A | |
| SCHEMBL26580904 | 0.71 | KDM4E (0.33) | KDM4EMAPK1HSD17B10NPC1RAB9A | |
| SCHEMBL26580903 | 0.71 | KDM4E (0.33) | KDM4EMAPK1HSD17B10NPC1RAB9A | |
| SCHEMBL24785028 | 0.69 | ALDH1A1 (0.47) | HSD17B10NPC1RAB9AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-07-11 | — | — | US | disclosed |
| US-20230331717-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331717-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, KRAS, HRAS | KDM4E 3126/4885MAPK1 156/4885HSD17B10 3394/4885 |
| US-20240226113-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TP53, HRAS, KRAS | KDM4E 3543/4885MAPK1 416/4885HSD17B10 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.